Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Non-Typhoidal Salmonella conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Bharat Biotech
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Non-Typhoidal Salmonella (NTS) conjugate vaccine is a bivalent vaccine candidate developed by Bharat Biotech to prevent invasive Non-Typhoidal Salmonella (iNTS) infections. The vaccine targets the two most common serovars associated with iNTS disease: *Salmonella enterica* serovar Typhimurium and *Salmonella enterica* serovar Enteritidis. It utilizes a conjugate platform where the O-polysaccharide (O-antigen) from these bacteria is chemically linked to a carrier protein, such as tetanus toxoid. This conjugation enhances the immune response by engaging T-cells, which is particularly critical for providing protection in infants and young children who do not respond well to pure polysaccharide vaccines. The vaccine is currently in Phase 3 clinical development, aiming to address a significant public health burden in sub-Saharan Africa and other endemic regions.
- Other names
- NTS ConjugatesNon-Typhoidal Salmonella vaccineiNTS vaccineBharat Biotech NTS vaccine
02
Targets
O9 (Salmonella Enteritidis O-antigen polysaccharide)Salmonella enterica serovar Typhimurium O:4 O-antigen polysaccharideO-antigen (Salmonella Typhimurium O-antigen polysaccharide)
Beyond the preview
Go deeper on Non-Typhoidal Salmonella conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Non-Typhoidal Salmonella conjugate vaccine.